Accuray’s Downturn Highlights a Missed Opportunity: Growing Linac Sales Through ISO Support and Pre-Owned Systems
Accuray’s declining financial performance (NASDAQ: ARAY) underscores a broader truth in the radiation therapy industry: OEMs benefit when they embrace independent service organizations and the pre-owned linac market, something Accuray has not done. As Accuray faces ongoing revenue challenges, its…